Bioanalytical method development and validation for quantification of amivantamab in rat plasma by LC-MS/MS

被引:0
作者
Pridhvi Krishna Gaddey
Raja Sundararajan
机构
[1] GITAM School of Pharmacy,Department of Pharmaceutical Analysis
[2] GITAM (Deemed to Be University),undefined
来源
Future Journal of Pharmaceutical Sciences | / 10卷
关键词
Amivantamab; LC-MS/MS; Rat plasma; Validation;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 48 条
[1]  
Xia Y(2023)The efficacy and hemorheological indexes of ginseng and its active components for patients with non-small cell lung cancer: a systematic review and meta-analysis J Oncol 2023 3144086-367
[2]  
Han H(2008)Small cell lung cancer Mayo Clin Proc 83 355-751
[3]  
Gu R(2020)Emerging therapeutic agents for advanced non-small cell lung cancer J Hematol Oncol 13 58-49
[4]  
Tao R(1985)Smoking and other risk factors for lung cancer in women J Natl Cancer Inst 74 747-500
[5]  
Lu K(2003)Epidemiology of lung cancer Chest 123 21-206
[6]  
Sun Z(2022)Analysis of the efficacy and safety of amivantamab in non-small cell lung cancer patients with EGFR/MET gene abnormalities: a single center's experience Chin J Cancer 25 493-16
[7]  
Shen S(2023)Targeting EGFR Exon 20 insertion mutation in non-small cell lung cancer: amivantamab and mobocertinib Ann Pharmacother 57 198-undefined
[8]  
Wang A(2022)Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer Expert Rev Anticancer Ther 22 3-undefined
[9]  
Lu Y(2022)Development and validation of a LC-MS/MS method for simultaneous quantification of Ivabradine and metoprolol in rat plasma J Pharmacol Toxicol Methods 116 107186-undefined
[10]  
Sher T(2019)AAPS Workshop Report on ICH M10 AAPS 22 10-undefined